The Journal of Urology
Volume 182, Issue 6 , Pages 2569-2577 , December 2009

Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors

  • Camillo Porta

      Affiliations

    • Financial interest and/or other relationship with Bayer-Schering, Pfizer Oncology, Hoffman La Roche, Novartis and Wyeth.
    • Corresponding Author InformationCorrespondence: Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, Istituto Di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Piazzale C. Golgi 19, I-27100 Pavia, Italy (telephone: +39-0382-501355; FAX: +39-0382-526223)
    • ,
  • Robert A. Figlin

      Affiliations

    • Financial interest and/or other relationship with Wyeth.

Received 30 December 2008

References 

  1. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988
  2. Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park). 2007;21:1175
  3. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481
  4. Fresno-Vara JA, Casado E, De Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193
  5. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 2000;14:1027
  6. Testa JR, Bellacosa A. Akt plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:10983
  7. Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene. 2001;20:6073
  8. Lu Y, Lin YZ, LaPushin R, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 1999;18:7034
  9. Simpson L, Parson R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264:29
  10. Brenner W, Farber G, Herget T, et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002;99:53
  11. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496
  12. Hara S, Oya M, Mizuno R, et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol. 2005;16:928
  13. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424
  14. Altomare DA, Testa JR. Perturbations of the Akt signalling pathway in human cancer. Oncogene. 2005;24:7455
  15. Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene. 2006;25:6423
  16. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004
  17. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signalling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995
  18. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257
  19. Dhillon AS, Hagan S, Roth O, et al. MAP kinase signalling pathway in cancer. Oncogene. 2007;26:3279
  20. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392
  21. Suresh BCV, Babar SM, Song EJ, et al. Kinetic analysis of the MAPK and PI3K/Akt signaling pathways. Mol Cells. 2008;25:397
  22. Lee JT, Steelman LS, Chappel WH, et al. Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle. 2008;7:631
  23. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280
  24. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93:3636
  25. Sourbier C, Lindner V, Lang H, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res. 2006;66:5130
  26. He L, Fan C, Gillis A, et al. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta. 2007;1772:1134
  27. Verheijen JC, Zask A. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs. Drugs Fut. 2007;32:537
  28. Yu K, Lucas J, Zhu T, et al. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther. 2005;4:538
  29. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008;68:206
  30. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851
  31. Lindsley CW, Barnett SF, Layton ME, et al. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets. 2008;8:7
  32. Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther. 1995;66:39
  33. Berkovic D. Cytotoxic etherphospholipid analogues. Gen Pharmacol. 1998;31:511
  34. Hilgard P, Klenner T, Stekar J, et al. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol. 1993;32:90
  35. Grunicke HH, Maly K, Uberall F, et al. Cellular signalling as a target in cancer chemotherapy (Phospholipid analogues as inhibitors of mitogenic signal transduction). Adv Enzyme Regul. 1996;36:385
  36. Arthur G, Bittman R. The inhibition of cell signalling pathways by antitumor ether lipids. Biochim Biophys Acta. 1998;1390:85
  37. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093
  38. Li X, Luwor R, Lu Y, et al. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by Perifosine in PTEN-deficient cancer cells. Oncogene. 2006;25:525
  39. Patel V, Lahusen T, Sy T, et al. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res. 2002;62:1401
  40. Elrod HA, Lin YD, Yue P, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther. 2007;6:2029
  41. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer. 2002;38:1615
  42. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004;10:7450
  43. Vink SR, Schellens JH, Beijnen JH, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol. 2006;80:207
  44. Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol. 2007;25(suppl.):abstract 15622.
  45. Birch R, Chawla S, Nemunaitis J, et al. Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma. J Clin Oncol. 2007;25(suppl.):abstract 10059.
  46. Schreeder MT, Figlin RA, Stephenson JJ, et al. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. J Clin Oncol. 2008;26(suppl.):abstract 16024.
  47. Allerton JP, Ebrahimi B, Schreeder MT, et al. Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC). J Clin Oncol. 2008;26(suppl.):abstract 14565.
  48. Holland WS, Mack PC, Gandara DR, et al. Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine. J Clin Oncol. 2008;26(suppl.):abstract 16083.
  49. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/Akt signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187
  50. Tunuguntla HS, Jorda M. Diagnostic and prognostic maolecular markers in renal cell carcinoma. J Urol. 2008;179:2096

 Study received institutional review board approval.

 See Editorial on page 2555.

 For another article on a related topic see page 2920.

PII: S0022-5347(09)02120-X

doi: 10.1016/j.juro.2009.08.085

The Journal of Urology
Volume 182, Issue 6 , Pages 2569-2577 , December 2009

Article Tools

* Image Usage & Resolution